UM, AstraZeneca partner to boost lung cancer screenings

Big institutions in Maryland are joining forces to enhance community-based lung cancer screenings for those at high risk. On Tuesday, experts representing the University of Maryland Greenebaum Comprehensive Cancer Center and pharmaceutical company AstraZeneca said early detection can have a bigger impact on a patient’s chances of survival than chemotherapy and immunotherapy.